title: Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis.
authors: M
authors: M
authors: Villar
authors: G
authors: G
authors: Sotgiu
authors: L
authors: L
authors: D'Ambrosio
authors: E
authors: E
authors: Raymundo
authors: L
authors: L
authors: Fernandes
authors: J
authors: J
authors: Barbedo
authors: N
authors: N
authors: Diogo
authors: C
authors: C
authors: Lange
authors: R
authors: R
authors: Centis
authors: G B
authors: GB
authors: Migliori
mesh_terms: D000081:Acetamides / Q000494:pharmacology*; D000328:Adult; D000583:Amikacin / Q000008:administration & dosage; D000995:Antitubercular Agents / Q000627:therapeutic use; D002207:Capreomycin / Q000008:administration & dosage; D064420:Drug-Related Side Effects and Adverse Reactions; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy*; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage; D006801:Humans; D055552:Infectious Disease Medicine / Q000379:methods; D007538:Isoniazid / Q000008:administration & dosage; D007612:Kanamycin / Q000008:administration & dosage; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000494:pharmacology*; D012293:Rifampin / Q000008:administration & dosage
chemical_list: D000081:Acetamides; D000995:Antitubercular Agents; D024841:Fluoroquinolones; D023303:Oxazolidinones; D002207:Capreomycin; D007612:Kanamycin; D000583:Amikacin; D000069349:Linezolid; D007538:Isoniazid; D012293:Rifampin